Highlights
- Ziltivekimab robustly lowers inflammatory biomarkers including free interleukin-6 and high-sensitivity C-reactive protein (hsCRP) in patients with atherosclerosis and chronic kidney disease (CKD).
- Phase 2 trials (RESCUE and RESCUE-2) demonstrated dose-dependent biomarker reductions, improvements in neutrophil-lymphocyte ratio (NLR), and a favorable safety profile.
- The pivotal ZEUS trial involving 6376 patients revealed that despite profound biomarker suppression, ziltivekimab did not reduce major adverse cardiovascular events (MACE) compared with placebo.
- The dissociation between biomarker modulation and clinical events underscores current knowledge gaps in targeting IL-6 for cardiovascular risk reduction and nuances of residual inflammatory risk.
Background
Specialty calculators
For clinical reference; use professional judgment.
